During dose escalation (n = 21), the most common treatment-emergent AEs reported in at least 15% of total patients were nausea (47.6%), fatigue (42.9%), diarrhea (38.1%), constipation (33.3%), AST increased (28.6%), anemia, decreased white blood cell count, vomiting (23.8% each), and abdominal pain, alopecia, ALT increased, blood alkaline phosphatase increased, decreased appetite, dyspnea, neutrophil count decreased (19% each; Supplementary Table S2). This evidence concerns the gene GPT and anemia.